Boston University (BU) is the home of CARB-X and the heart of its operations. Based at the BU School of Law, CARB-X is an example of BU’s leadership, collaboration, and engagement with the larger world: a global partnership confronting a dire public health threat – antibiotic-resistant bacteria. Led by Executive Director Kevin Outterson, N. Neal Pike Scholar in Health and Disability Law at the School of Law, the program facilitates the creation of new vaccines, diagnostics, and therapies around the world to stop the spread of disease – a goal with increasing urgency.
And BU has the expertise to achieve it. A major global research university, BU is a member of the prestigious Association of American Universities. BU’s transformative, cutting-edge research – sponsored annually by hundreds of millions of dollars in awards – addresses society’s most pressing challenges.